Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis. J of Skin 2017, 1 (3.1), s10. https://doi.org/10.25251/skin.1.supp.9.